By Jennifer Ahlstrom | Posted - Oct 7th, 2017





Clinical Trial: BiTE Antibody in Myeloma for Relapsed/Refractory Patients

Bi-specfic T-cell engages (also called BiTEs) are coming to myeloma clinical trials. BiTEs are artificial bispecific monoclonal antibodies which go after two targets - one on the T cell and one on the cancer cell. The antibody directs a patient's immune system (specifically the T cell) to link their T cells to the cancer cell, killing it. BiTE is a registered trademark of the company Micromet AG.

Specifically, the strong killing power of the T cell's CD3 receptor is connected with a specific protein that is found on the surface of myeloma cells. In the case of the BFCR4350A clinical trial, the T cell connects with a Fc receptor-like protein with five targets (FCRH5; CD307; FCRL5; IRTA2; BXMAS1). 

 This is a phase I, open-label, dose-escalation study of BFCR4350A administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma. 

There are 6 active sites in the United States for this trial (Mayo Clinic Scottsdale, City of Hope, University of Colorado, Dana Farber, UPENN, Sarah Cannon). One site in Canada and another in Australia are also open. 

Learn more and connect with this trial directly at:

Clinical Trial

Find eligible clinical trials for your myeloma here:

Find all Clinical Trials

Jennifer Ahlstrom
About the Author

Jennifer Ahlstrom - Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.


Add a Comment

Michael - You should do a special report on Janssen's BiTE trial. I am in that study. Two days after the first very low dose shot, my Kappa Light Chain numbers dropped over 99%, from 386 to 3. Two weeks later, UNDETECTED. Protein levels in urine dropped from 200 to 190 after 4 weeks and is now UNDETECTABLE. And the biggie, the plasma in my marrow went from 50% to UNDETECTABLE. Better news? This trial has amazing effects for virtually everyone who joins. A friend of ours who has been struggling with MM got in the study. After 2 days, her level dropped from over 1,600 to 75. Two weeks later from 75 to 9. Hope to hear more on the Myeloma Crowd and want to get the word about this trial out!!!!

Reply from Jennifer - So glad you are having such amazing results! We will be sure to cover it!



Thanks to our Myeloma Crowd Community sponsors:

.                         .       .